
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical-stage biopharmaceutical company with a promising pipeline in the areas of immunology, inflammation, and oncology. Positive updates from competitors or FDA alignment on a regulatory filing strategy may lead to a rise in the stock price. However, there are also risks, including clinical development risk, capital markets and dilution risk, and pricing risk, that may impact the company's success and stock performance.
Bears say
Gossamer Bio is a clinical-stage biopharmaceutical company that has recently reported disappointing Phase 3 data for its lead drug candidate, seralutinib, in pulmonary arterial hypertension (PAH). While the company remains hopeful about its sub-group analyses and potential path to approval, there are concerns about the drug's overall efficacy and market opportunity. In addition, the company is facing financial challenges and will likely require additional funding to reach commercialization, which could put pressure on its stock price.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares